Top-Rated StocksTop-RatedNYSE:BHVN Biohaven (BHVN) Stock Price, News & Analysis $36.90 -0.02 (-0.05%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$36.06â–Ľ$37.5850-Day Range$33.79â–Ľ$41.7352-Week Range$16.45â–Ľ$62.21Volume593,468 shsAverage Volume1.16 million shsMarket Capitalization$3.26 billionP/E RatioN/ADividend YieldN/APrice Target$54.44 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Biohaven alerts: Email Address Biohaven MarketRank™ Stock AnalysisAnalyst RatingBuy3.09 Rating ScoreUpside/Downside47.5% Upside$54.44 Price TargetShort InterestBearish11.65% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.41Based on 10 Articles This WeekInsider TradingAcquiring Shares$1.01 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($8.92) to ($6.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.38 out of 5 starsMedical Sector271st out of 910 stocksPharmaceutical Preparations Industry115th out of 426 stocks 4.5 Analyst's Opinion Consensus RatingBiohaven has received a consensus rating of Buy. The company's average rating score is 3.09, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBiohaven has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Biohaven's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.65% of the outstanding shares of Biohaven have been sold short.Short Interest Ratio / Days to CoverBiohaven has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Biohaven has recently increased by 5.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBiohaven does not currently pay a dividend.Dividend GrowthBiohaven does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BHVN. Previous Next 2.5 News and Social Media Coverage News SentimentBiohaven has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Biohaven this week, compared to 4 articles on an average week.Search InterestOnly 6 people have searched for BHVN on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows3 people have added Biohaven to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biohaven insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,013,028.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders16.00% of the stock of Biohaven is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.78% of the stock of Biohaven is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biohaven's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biohaven are expected to grow in the coming year, from ($8.92) to ($6.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biohaven is -5.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biohaven is -5.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiohaven has a P/B Ratio of 9.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Biohaven's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. About Biohaven Stock (NYSE:BHVN)Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Read More BHVN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BHVN Stock News HeadlinesSeptember 6 at 3:35 AM | americanbankingnews.comBiohaven (NYSE:BHVN) Stock Rating Reaffirmed by Royal Bank of CanadaSeptember 5 at 11:53 AM | nl.investing.comBernstein opent dekking voor Biohaven-aandelen en voorspelt aanzienlijke winstSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.September 5 at 11:53 AM | markets.businessinsider.comRBC Capital Sticks to Their Buy Rating for Biohaven Ltd. (BHVN)September 5 at 4:13 AM | americanbankingnews.comBiohaven (NYSE:BHVN) Receives New Coverage from Analysts at Sanford C. BernsteinSeptember 3, 2024 | americanbankingnews.comShort Interest in Biohaven Ltd. (NYSE:BHVN) Increases By 5.1%August 28, 2024 | americanbankingnews.comBiohaven Ltd. (NYSE:BHVN) Receives $54.38 Average Target Price from BrokeragesAugust 27, 2024 | markets.businessinsider.comOptimistic Outlook: Buy Rating on Biohaven Ltd. for Strategic Approach and Promising R&D PipelineSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 27, 2024 | msn.comBofA starts Biohaven at buy, cites "fast-follower" approachAugust 14, 2024 | markets.businessinsider.comBuy Rating Backed by Biohaven Ltd.’s Promising Clinical Pipeline and Pharmacokinetic AdvancementsAugust 9, 2024 | markets.businessinsider.comBuy Rating on Biohaven Ltd. Affirmed Amid Promising BHV-1300 Clinical Trial Results and Undervalued Stock PotentialAugust 9, 2024 | markets.businessinsider.comBHVN Stock Earnings: Biohaven Misses EPS for Q2 2024August 9, 2024 | msn.comDo Analysts Think That Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Is a Good GLP-1 and Weight Loss Stock to Invest In?August 8, 2024 | prnewswire.comBiohaven Reports Second Quarter 2024 Financial Results and Recent Business DevelopmentsJuly 26, 2024 | seekingalpha.comBiohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA TreatmentJuly 25, 2024 | msn.comMorgan Stanley starts Biohaven at overweight, cites broad pipelineJuly 25, 2024 | msn.comMorgan Stanley Initiates Coverage of Biohaven (BHVN) with Overweight RecommendationSee More Headlines Receive BHVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:BHVN Previous SymbolNASDAQ:BHVN CUSIPN/A CIK1689813 Webwww.biohavenpharma.com Phone203-404-0410FaxN/AEmployees239Year FoundedN/APrice Target and Rating Average Stock Price Target$54.44 High Stock Price Target$59.00 Low Stock Price Target$36.00 Potential Upside/Downside+47.5%Consensus RatingBuy Rating Score (0-4)3.09 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($6.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-408,170,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-212.83% Return on Assets-157.42% Debt Debt-to-Equity RatioN/A Current Ratio3.27 Quick Ratio3.27 Sales & Book Value Annual Sales$462.51 million Price / Sales7.04 Cash FlowN/A Price / Cash FlowN/A Book Value$4.06 per share Price / Book9.09Miscellaneous Outstanding Shares88,292,000Free Float74,165,000Market Cap$3.26 billion OptionableOptionable Beta1.30 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Vladimir Coric M.D. (Age 53)Chairman & CEO Comp: $1.96MMr. Matthew Buten (Age 63)Chief Financial Officer Comp: $1.05MDr. Bruce D. Car DACVP (Age 62)Ph.D., Chief Scientific Officer Comp: $883.03kMs. Kimberly Gentile (Age 58)Senior Vice President of Clinical Operations Comp: $858.65kMs. Deb YoungDirector of Regulatory Affairs & OperationsMr. George C. Clark (Age 40)VP & Chief Accounting Officer Ms. Jennifer PorcelliVice President of Investor RelationsMr. Warren Volles J.D.General Counsel & Chief Legal OfficerMr. Clifford Bechtold M.S.President, GM of Biohaven Ireland & Chief Compliance OfficerMr. John Tilton (Age 56)Chief Commercial Officer of Rare Diseases More ExecutivesKey CompetitorsGinkgo BioworksNYSE:DNASarepta TherapeuticsNASDAQ:SRPTVaxcyteNASDAQ:PCVXCatalentNYSE:CTLTQiagenNYSE:QGENView All CompetitorsInsiders & InstitutionsClearbridge Investments LLCBought 69,180 shares on 8/27/2024Ownership: 0.543%Point72 Asset Management L.P.Sold 732,238 shares on 8/19/2024Ownership: 0.201%Creative PlanningSold 1,636 shares on 8/16/2024Ownership: 0.013%Algert Global LLCBought 412 shares on 8/16/2024Ownership: 0.008%Quarry LPBought 4,300 shares on 8/16/2024Ownership: 0.006%View All Insider TransactionsView All Institutional Transactions BHVN Stock Analysis - Frequently Asked Questions How have BHVN shares performed this year? Biohaven's stock was trading at $42.80 at the beginning of 2024. Since then, BHVN stock has decreased by 13.8% and is now trading at $36.90. View the best growth stocks for 2024 here. How were Biohaven's earnings last quarter? Biohaven Ltd. (NYSE:BHVN) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($3.64) earnings per share for the quarter, missing the consensus estimate of ($1.72) by $1.92. When did Biohaven IPO? Biohaven (BHVN) raised $124 million in an IPO on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers. Who are Biohaven's major shareholders? Top institutional investors of Biohaven include Farallon Capital Management LLC (2.55%), Perceptive Advisors LLC (1.68%), Armistice Capital LLC (1.58%) and ARS Investment Partners LLC (1.07%). Insiders that own company stock include John W Childs, Vlad Coric, Gregory Bailey, Matthew Buten, George C Clark, Irina Antonijevic, Julia P Gregory, Elyse Stock, James Engelhart and Declan Doogan. View institutional ownership trends. How do I buy shares of Biohaven? Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Biohaven own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biohaven investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD) and QUALCOMM (QCOM). This page (NYSE:BHVN) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biohaven Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biohaven With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BHVN Stock Alerts